NPM1 and acute myeloid leukemia: Of clinical relevance, therapeutic targeting of either NPM1 or FLT3-ITD mutations might thus have a transient benefit in restraining disease progression and debulking the leukemia but is unlikely to be curative since will not target the AML-initiating/preleukemic cells.